Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Jacob Hesselvig Fredsøe

Om AU

Jacob Hesselvig Fredsøe

Lektor

Profile photo

Jacob Hesselvig Fredsøe

Lektor

  • Institut for Klinisk Medicin - Molekylær Medicinsk afdeling (MOMA)
Adressetype: Postaddresse.
Brendstrupgårdsvej 21A
8200
Aarhus N
Danmark

E-mail: jcf@clin.au.dk

Ansættelse

Lektor

Institut for Klinisk Medicin - Molekylær Medicinsk afdeling (MOMA)

Aarhus Universitet

Aarhus N, Danmark

1 nov. 2022 → nu

Adjunkt

Institut for Klinisk Medicin - Molekylær Medicinsk afdeling (MOMA)

Aarhus Universitet

Aarhus N, Danmark

1 aug. 2018 → 1 nov. 2022

Institut for Klinisk Medicin - Molekylær Medicinsk afdeling (MOMA)

Aarhus Universitet

Aarhus N, Danmark

11 jul. 2014 → 2 aug. 2018

Institut for Molekylærbiologi og Genetik - Genom stabilitet og teknologi

Aarhus Universitet

Aarhus C, Danmark

9 maj 2014 → 16 jul. 2014

Institut for Molekylærbiologi og Genetik - Genom stabilitet og teknologi

Aarhus Universitet

Aarhus C, Danmark

11 apr. 2014 → 9 maj 2014

Institut for Molekylærbiologi og Genetik - Genom stabilitet og teknologi

Aarhus Universitet

Aarhus C, Danmark

10 feb. 2012 → 11 apr. 2014

Institut for Molekylærbiologi og Genetik

Aarhus Universitet

Aarhus C, Danmark

29 jul. 2011 → 10 feb. 2012

SU ph.d-stipendiat

Molekylærbiologisk Institut

Aarhus Universitet

Aarhus C, Danmark

21 dec. 2010 → 10 feb. 2011

Publikationer

Danish Prostate Cancer Consortium Study 1 (DPCC-1) Protocol: Multicenter prospective validation of the urinebased 3-microRNA biomarker model uCaP

Fredsøe, J. H., Glud, E. N., Boesen, L. P., Løgager, V., Poulsen, M. H., Pedersen, B. G., Borre, M. & Sørensen, K. D., nov. 2023, I: BMJ Open. 13, 11, 5 s., e077020.

Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population

Fredsøe, J. H., Sandahl, M., Vedsted, P., Jensen, J. B., Ulhøi, B. P., Borre, M., Pedersen, B. G. & Sørensen, K. D., 1 aug. 2023, I: European urology oncology.

Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer

Nørgaard, M., Bjerre, M. T., Fredsøe, J., Vang, S., Jensen, J. B., De Laere, B., Grönberg, H., Borre, M., Lindberg, J. & Sørensen, K. D., apr. 2023, I: Clinical Chemistry. 69, 4, s. 386-398 13 s.

Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach

Risør, B. W., Tayyari Dehbarez, N., Fredsøe, J. H., Sørensen, K. D. & Pedersen, B. G., nov. 2022, I: Applied Health Economics and Health Policy. 20, 6, s. 867-880 14 s.

Recurrence rate after radical prostatectomy following primary staging of high-risk prostate cancer with 68Ga-PSMA PET/CT

Klingenberg, S., Fredsøe, J. H., Sørensen, K. D., Ulhøi, B. P., Borre, M., Jochumsen, M. R. & Bouchelouche, K., nov. 2022, I: Acta Oncologica. 61, 10, s. 1289-1294 6 s.

A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer

Ipsen, M. B., Sørensen, E. M. G., Thomsen, E. A., Weiss, S., Haldrup, J., Dalby, A., Palmfeldt, J., Bross, P., Rasmussen, M., Fredsøe, J., Klingenberg, S., Jochumsen, M. R., Bouchelouche, K., Ulhøi, B. P., Borre, M., Mikkelsen, J. G. & Sørensen, K. D., sep. 2022, I: Oncogene. 41, 37, s. 4271-4281 11 s.

Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine

Fredsøe, J., Rasmussen, M., Tin, A. L., Vickers, A. J., Borre, M., Sørensen, K. D. & Lilja, H., sep. 2022, I: Scientific Reports. 12, 7 s., 15193.

Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling

Salachan, P. V., Rasmussen, M., Fredsøe, J., Ulhøi, B., Borre, M. & Sørensen, K. D., jan. 2022, I: Genome Medicine. 14, 18 s., 9.

The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

Hansen, E. K. B., Fredsøe, J. H., Okholm, T. L. H., Ulhøi, B. P., Klingenberg, S., Jensen, J. B., Kjems, J., Bouchelouche, K., Borre, M., Damgaard, C. K., Pedersen, J. S., Kristensen, L. S. & Sørensen, K. D., jan. 2022, I: Genome Medicine. 14, 1, 8.

Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence

Rasmussen, M., Fredsøe, J., Tin, A. L., Vickers, A. J., Ulhøi, B., Borre, M., Eastham, J., Ehdaie, B., Guillonneau, B., Laudone, V., Scardino, P. T., Touijer, K., Sørensen, K. D. & Lilja, H., 2022, I: British Journal of Cancer. 126, 7, s. 1004-1009 6 s.

Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors

Andersen, L. B., Nørgaard, M., Rasmussen, M., Fredsøe, J., Borre, M., Ulhøi, B. P. & Sørensen, K. D., okt. 2021, I: Journal of Pathology. 255, 2, s. 155-165 11 s.

High-throughput and automated acoustic trapping of extracellular vesicles to identify microRNAs with diagnostic potential for prostate cancer

Ku, A., Fredsøe, J. H., Sørensen, K. D., Borre, M., Evander, M., Laurell, T., Lilja, H. & Ceder, Y., mar. 2021, I: Frontiers in Oncology. 11, 13 s., 631021.

68Ga-PSMA PET/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer

Klingenberg, S., Jochumsen, M. R., Ulhøi, B. P., Fredsøe, J. H., Sørensen, K. D., Borre, M. & Bouchelouche, K., feb. 2021, I: Journal of Nuclear Medicine. 62, 2, s. 214-220 7 s.

Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential

Bjerre, M. T., Nørgaard, M., Larsen, O. H., Jensen, S. Ø., Strand, S. H., Østergren, P., Fode, M., Fredsøe, J., Ulhøi, B. P., Mortensen, M. M., Jensen, J. B., Borre, M. & Sørensen, K. D., jun. 2020, I: Cells. 9, 6, 17 s., 1362.

A genetic risk assessment for prostate cancer influences patients’ risk perception and use of repeat PSA testing: a cross-sectional study in Danish general practice

Fredsøe, J. H., Kirkegaard, P., Edwards, A., Vedsted, P., Sørensen, K. D. & Bro, F., maj 2020, I: British Journal of General Practice Open . 4, 2, 11 s., 1039.

Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential

Fredsøe, J., Rasmussen, A. K. I., Mouritzen, P., Bjerre, M. T., Østergren, P., Fode, M., Borre, M. & Sørensen, K. D., 2020, I: Diagnostics. 10, 4, 13 s., 188.

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial

Fredsøe, J., Koetsenruijter, J., Vedsted, P., Kirkegaard, P., Væth, M., Edwards, A., Ørntoft, T. F., Sørensen, K. D. & Bro, F., 2020, I: PLOS Medicine. 17, 2, s. e1003033 14 s., e1003033.

Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells

Laursen, E. B., Fredsøe, J., Schmidt, L., Strand, S., Kristensen, H., Ildor Rasmussen, A. K., Daugaard, T. F., Mouritzen, P., Høyer, S., Kristensen, G., Stroomberg, H. V., Brasso, K., Røder, M. A., Borre, M. & Sørensen, K. D., dec. 2019, I: The American Journal of Pathology. 189, 12, s. 2377-2388 12 s.

A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine

Fredsøe, J., Rasmussen, A. K. I., Mouritzen, P., Borre, M., Ørntoft, T. & Sørensen, K. D., 1 nov. 2019, I: International Journal of Cancer. 145, 9, s. 2558-2567 10 s.

Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine

Fredsøe, J., Rasmussen, A. K. I., Laursen, E. B., Cai, Y., Howard, K. A., Pedersen, B. G., Borre, M., Mouritzen, P., Òrntoft, T. & Sørensen, K. D., apr. 2019, I: Clinical Chemistry. 65, 4, s. 540-548 9 s.

Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer

Bjerre, M. T., Strand, S. H., Nørgaard, M., Kristensen, H., Rasmussen, A. K., Mortensen, M. M., Fredsøe, J., Mouritzen, P., Ulhøi, B., Ørntoft, T., Borre, M. & Sørensen, K. D., mar. 2019, I: International Journal of Molecular Sciences . 20, 5, 1173.

Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine

Fredsøe, J., Rasmussen, A. K. I., Thomsen, A. R., Mouritzen, P., Høyer, S., Borre, M., Ørntoft, T. F. & Sørensen, K. D., dec. 2018, I: European Urology Focus. 4, 6, s. 825-833 9 s.

Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients

Schmidt, L., Fredsøe, J., Kristensen, H., Strand, S. H., Rasmussen, A., Høyer, S., Borre, M., Mouritzen, P., Ørntoft, T. & Sørensen, K. D., 1 sep. 2018, I: Annals of Oncology. 29, 9, s. 2003-2009 7 s.

Top2 and Sgs1-Top3 Act Redundantly to Ensure rDNA Replication Termination

Mundbjerg, K., Jørgensen, S. W., Fredsøe, J., Nielsen, I., Pedersen, J. M., Bentsen, I. B., Lisby, M., Bjergbaek, L. & Andersen, A. H., 2 dec. 2015, I: P L o S Genetics. 11, 12, s. e1005697 24 s.

DNA Topoisomerases Are Required for Preinitiation Complex Assembly during GAL Gene Activation

Roedgaard, M., Fredsoe, J., Pedersen, J. M., Bjergbaek, L. & Andersen, A. H., 14 jul. 2015, I: PLOS ONE. 10, 7, s. 1-15 15 s., e0132739.

The importance of Topoisomerases for Chromatin Regulated Genes

Fredsøe, J. C., 18 jun. 2014, Aarhus University, Faculty of Science and Technology. 195 s.

The importance of topoisomerases for chromatin regulated genes

Fredsøe, J. C., Pedersen, J. M., Rødgaard, M. T. & Andersen, A. H., 26 aug. 2013. 1 s.

DNA hairpins as temperature switches, thermometers and ionic detectors.

Jonstrup, A. T., Fredsøe, J. C. & Andersen, A. H., 5 maj 2013, I: Sensors. 13, 5, s. 5937-5944

DNA Topoisomerases Maintain Promoters in a State Competent for Transcriptional Activation in Saccharomyces cerevisiae

Pedersen, J. M., Fredsøe, J. C., Rødgaard, M. T., Andreasen, L., Mundbjerg, K., Kruhøffer, M., Brinch, M., Schierup, M. H., Bjergbæk, L. & Andersen, A. H., 20 dec. 2012, I: P L o S Genetics. 8, 12 e1003128, s. 1-15 15 s.

The importance of DNA topoisomerases and DNA topology for genome and transcriptome maintenance

Mundbjerg, K., Pedersen, J. M., Nielsen, I., Fredsøe, J. C., Christensen, H., Ingerslev, A. K., Jørgensen, S. W., Pedersen, L. H. & Andersen, A. H., 2010.

Aktiviteter

Nyt fra forskningsfronten

Jacob Hesselvig Fredsøe (Foredragsholder)

9 okt. 2023

Medejer i MediSkill ApS

Jacob Hesselvig Fredsøe (Deltager)

1 sep. 2022 → …

Risk-adapted screening with SNPs: Results from the ProCaRis trial

Jacob Hesselvig Fredsøe (Foredragsholder)

9 jul. 2021

Results from using SNP based risk stratification for personalized PSA screening in general practice

Jacob Hesselvig Fredsøe (Foredragsholder)

24 jun. 2021

Data Manager ved Frontal Lobe ApS

Jacob Hesselvig Fredsøe (Deltager)

1 nov. 2018 → …

AACR Annual Meeting 2017

Jacob Christian Fredsøe (Deltager)

1 apr. 2017 → 5 apr. 2017

Circulating Biomarkers World Congress 2015

Jacob Christian Fredsøe (Deltager)

23 mar. 2015 → 24 mar. 2015

Mechanisms of Eukaryotic Transcription

Jacob Christian Fredsøe (Deltager)

27 aug. 2013 → 31 aug. 2013

DNA Topoisomerases maintain promoters in a state competent for transcriptional activation in Saccharomyces cerevisiae.

Jacob Christian Fredsøe (Foredragsholder)

21 jun. 2013

Presse/medie

Biomarkører i urinprøver kan afsløre prostatakræft

Jacob Christian Fredsøe

02/06/2018

1 Mediebidrag